[ad_1]
March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone of medical diagnostics, known for its non-ionizing and non-invasive nature. Since nearly 40% of MRI procedures require the use of contrast agents for optimal sensitivity, there is a growing need for safer and more effective alternatives to gadolinium-based contrast agents (GBCA). Although widely used, GBCA still suffers from problems such as nephrotoxicity, long-term tissue deposition, and limited cell specificity, which allows patients with renal insufficiency to safely perform contrast-enhanced MRI scans, non-invasively map lymph nodes, track transplanted stem cells, and evaluate inflammation.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle approved for intravenous iron supplementation in the United States, Europe, and Canada. Since its clinical introduction in 2009, Ferumoxytol-enhanced MRI (FE-MRI) has significantly changed CE-MRI practice. Compared to GBCA, Ferumoxytol stands out for its excellent safety profile, higher relaxivity, extended blood pool half-life, non-renal metabolism and versatility. These attributes give FE-MRI numerous technical advantages, such as reduced contrast agent dose, extended imaging window, no nephrotoxicity, higher MRI time efficiency, and molecular imaging capabilities.
Commentary articles recently published on the Internet national science review (NSR), written by the team of Professor Gu Ning of Nanjing University, carefully explores the clinical application and inherent technical advantages of FE-MRI. This comprehensive review not only bridges the gap between clinical needs and engineering innovations but also predicts the potential development trajectory of FE-MRI. Specifically, the article deeply explores the broad clinical applications of FE-MRI in the diagnosis of the cardiovascular system, mononuclear phagocyte system, tumors, inflammation, and cell transplantation assessment, and conducts a detailed classification of clinical indications. Emerging topics such as micron-scale imaging of brain microvessels, fast FE-MRI imaging, multimodal image fusion, and vessel segmentation are highlighted, providing valuable insights for researchers in nanotechnology, (clinical) radiology, computer science, and related interdisciplinary fields. insights.
As the field of medical imaging continues to evolve, the emergence of ferumoxytol as a potential next-generation MRI contrast agent marks a major leap forward. Its comprehensive clinical utility, coupled with continued research and technological advancements, puts FE-MRI at the forefront of safer and more efficient diagnostic imaging. This promising trajectory has not only enhanced our understanding of various diseases but also opened up new avenues for non-invasive detailed exploration of the human body, making FE-MRI a beacon of innovation in the field of medical imaging.
For more information: https://academic.oup.com/nsr
[ad_2]
Source link